SCHEMBL2142149

SCHEMBL2142149

CN(C)Cc1cccc2[nH]cnc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
PKM P14618 2/20 0.53
CYP2D6 P10635 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 1/20 0.44
PARP1 P09874 2/20 0.42
KDM4A O75164 1/20 0.42
KDM4B O94953 1/20 0.42
KDM5C P41229 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
CYP1A2 P05177 1/20 0.40
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31693421 0.83 HTR2A (0.47) ALDH1A1PKMHTR2AHTR2CHTR2B
SCHEMBL763087 0.80 PARP1 (0.50) HTR2AHTR2CPARP1BRD4DRD4
SCHEMBL1647056 0.80 PARP1 (0.46) ALDH1A1PKMMEN1KMT2AHTR2A
SCHEMBL556764 0.78 PARP1 (0.51) ALDH1A1PKMMEN1KMT2AHTR2A
SCHEMBL28278904 0.77 HTR2A (0.44) ALDH1A1PKMHTR2AHTR2CPARP1
SCHEMBL7576839 0.77 PARP1 (0.50) ALDH1A1PKMMEN1KMT2AHTR2A
SCHEMBL20138342 0.77 PARP1 (0.46) ALDH1A1PKMMEN1KMT2AHTR2A
SCHEMBL3823364 0.77 PARP1 (0.46) ALDH1A1PKMMEN1KMT2AHTR2A
SCHEMBL23733959 0.76 GABRA1 (0.44) ALDH1A1PKMHTR2AHTR2CPARP1
SCHEMBL18611003 0.76 PARP1 (0.42) ALDH1A1PKMHTR2AHTR2CPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES CDK3, CCNI, CDK1 ALDH1A1 3598/4885PKM 564/4885CYP2D6 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.